Bart Frederick

A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis

Catharine Lisa Kauffman, Nancy Aria, Eiko Toichi et al. · Journal of Investigative Dermatology · 2004 · 276 citations

Pharmacy, Immunology, Pharmacokinetics +14

An Anti-IL-12p40 Antibody Down-Regulates Type 1 Cytokines, Chemokines, and IL-12/IL-23 in Psoriasis

Eiko Toichi, Gisela Torres, Thomas S. McCormick et al. · The Journal of Immunology · 2006 · 227 citations

Medicine, Dermatology, Immunology +17

Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization

A. Michael Lincoff, Dean J. Kereiakes, Mary Ann Mascelli et al. · Circulation · 2001 · 196 citations · Full text

Medicine, Cardiology, Pharmacology +17

A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis

Alice B. Gottlieb, Kevin D. Cooper, Thomas S. McCormick et al. · Current Medical Research and Opinion · 2007 · 104 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Pharmacokinetics, pharmacodynamics and safety of a human anti‐IL‐6 monoclonal antibody (sirukumab) in healthy subjects in a first‐in‐human study

Zhenhua Xu, Esther Bouman‐Thio, Craig Comisar et al. · British Journal of Clinical Pharmacology · 2011 · 96 citations · Full text

Medicine, Immunology, Pharmacology +17